Skip to main content Skip to search Skip to main navigation

FDA/CDRH: Proposed Guidances for FY 2022

The FDA’s Center for Devices and Radiological Health (CDRH) has published its lists with guidance documents intended to be published next year. At this stage CDRH is interested in receiving external feedback on whether the listed documents should be revised or withdrawn.

The documents have been split into three lists:

  • The A-list, for prioritized device guidance documents the FDA intends to publish during the fiscal year 2022
  • The B-list, for device guidance documents the FDA intends to publish as resources permit during the fiscal year 2022
  • A retrospective review list with final guidance documents issued in 1982, 1992, 2002, and 2012, with an option for withdrawl

Electronic comments can be submitted to www.regulations.gov.


Source:

FDA/CDRH: Proposed Guidelines for FY 2022

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Save Time and Money when Qualifying a Blister Packaging Line

Save Time and Money when Qualifying a Blister Packaging Line

Qualifying a blister packaging line is not only technically demanding, but also time-consuming and costly. Here you will find important tips on how to organise your qualification process in a cost-effective yet gmp-compliant manner.

Read more
Question of the Week | GMP-Verlag

What is the Role of the Logistics Service Provider?

Here's the answer:
Read more
News: EMA

EMA: Latest Report on the International GMP Inspection Programme for API Manufacturers

EMA has published a new report on the International Active Pharmaceutical Ingredient Inspection Programme, covering the period 2017–2024. During this time, the number of participating authorities increased from ten to 13. Information was shared on 936 inspected sites and 1,684 inspections.
Read more
News: EMA

EMA Updates Procedure for Coordinating GMP Inspections

EMA has updated its procedure for coordinating GMP inspections for centrally authorised medicinal products. Version 3 has applied since 10 September 2026 and replaces Version 2. The document forms part of the Compilation of Union Procedures on Inspections and Exchange of Information (CoUP), which comprises the EU procedures and templates for GMP and GDP inspections.
Read more
Swissmedic Updates Guidance on GMP Compliance of Foreign Manufacturers

Swissmedic Updates Guidance on GMP Compliance of Foreign Manufacturers

Swissmedic has revised its guidance document “GMP compliance by foreign manufacturers”. The new Version 7.0 has been valid since 7 September 2026. In particular, it introduces new provisions for demonstrating the GMP compliance of manufacturers inspected by the US FDA. 
Read more
Swissmedic Updates Requirements for Cooperation with Pre-Wholesalers

Swissmedic Updates Requirements for Cooperation with Pre-Wholesalers

Swissmedic has revised its Technical Interpretation “Market release and distribution in cooperation with a pre-wholesaler”. The document addresses market release and distribution where a Marketing Authorisation Holder works with a pre-wholesaler (logistics and distribution service provider).
Read more
Previous
Next